Antiviral prophylaxis in haematological patients: Systematic review and meta-analysis

European Journal of Cancer

Volumn 45, Issue 18, 2009, Pages 3131-3148

  Yahav, Dafna ^a   Gafter Gvili, Anat ^a   Muchtar, Eli ^a   Skalsky, Keren ^a   Kariv, Galia ^a   Yeshurun, Moshe ^a   Leibovici, Leonard ^a   Paul, Mical ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

Antiviral; Leukaemia; Prophylaxis; Stem cell transplantation

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BENZIMIDAVIR; GANCICLOVIR; RITUXIMAB; VALACICLOVIR; VALGANCICLOVIR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG WITHDRAWAL; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HUMAN; INFECTION PREVENTION; META ANALYSIS; MUCOSA INFLAMMATION; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ACYCLOVIR; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HUMANS; ORAL ULCER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBONUCLEOSIDES; TREATMENT OUTCOME;

EID: 70450248564     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.08.010     Document Type: Article

References (123)

1. Gratwohl A., Brand R., Frassoni F., et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transpl 36 (2005) 757-769
2. Kernan N.A., Bartsch G., Ash R.C., et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328 (1993) 593-602
3. Maltezou H.C., Kafetzis D.A., Abisaid D., et al. Viral infections in children undergoing hematopoietic stem cell transplant. Pediatr Infect Dis J 19 (2000) 307-312
4. Sandherr M., Einsele H., Hebart H., et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 17 (2006) 1051-1059
5. Ljungman P. Risk assessment in haematopoietic stem cell transplantation: viral status. Best Pract Res Clin Haematol 20 (2007) 209-217
6. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49:1-125 [CE1-7].
7. Ljungman P., de la Camara R., Cordonnier C., et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transpl 42 (2008) 227-240
8. Styczynski J., Reusser P., Einsele H., et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transpl (2008)
9. Staras S.A., Dollard S.C., Radford K.W., et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43 (2006) 1143-1151
10. Xu F., Sternberg M.R., Kottiri B.J., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296 (2006) 964-973
11. Kilgore P.E., Kruszon-Moran D., Seward J.F., et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 70 Suppl. 1 (2003) S111-S118
12. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.0.1 The Cochrane Collaboration. [updated September 2008].
13. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
14. Atkinson K., Arthur C., Bradstock K., et al. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group. Bone Marrow Transpl 16 (1995) 401-405
15. Atkinson K., Nivison-Smith I., Dodds A., et al. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989. Bone Marrow Transpl 21 (1998) 691-695
16. Atalla A., Maiolino A., Guimarães M.A., Guimarães A.C., and Nucci M. A non-randomized comparative study using different doses of acyclovir to prevent herpes simplex reactivation in patients submitted to autologous stem cell transplantation. Braz J Infect Dis 9 (2005) 330-335
17. Shereck E.B., Cooney E., van de Ven C., Della-Lotta P., and Cairo M.S. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr Blood Cancer 49 (2007) 306-312
18. Shereck E.B., Cooney E., van de Ven C., Della-Lotta P., and Cairo M.S. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Blood (2003) 102 [abstr. 5503]
19. Eisen D., Essell J., Broun E.R., Sigmund D., and DeVoe M. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transpl 31 (2003) 51-55
20. Rapaport D., Engelhard D., Tagger G., Or R., and Frenkel N. Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients. Transpl Infect Dis 4 (2002) 10-16
21. Gluckman E., Traineau R., Devergie A., Esperou-Bourdeau H., and Hirsch I. Prevention and treatment of CMV infection after allogeneic bone marrow transplant. Ann Hematol 64 Suppl. (1992) A158-A161
22. Boeckh M., Zaia J.A., Jung D., et al. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol Blood Marrow Transpl 4 (1998) 13-19
23. Bregante S., Bertilson S., Tedone E., et al. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transpl 26 (2000) 23-29
24. Bachier C., Shaughnessy P., Wall D., et al. Valganciclovir for the early prophylaxis of cytomegalovirus (CMV) infection after allogeneic stem cell transplantation. Blood (2004) 104 [abstr. 5074]
25. Ambinder R., Burns W., Lietman P., and Saral R. Prophylactic acyclovir therapy and herpes simplex. Ann Intern Med 100 (1984) 920-921
26. Postorino M, Dentamaro T, Picardi A, et al. Evaluation of two different strategies of CMV prophylaxis and pre-emptive therapy after allogeneic stem cell transplantation for haematological malignancies. In: European hematology association 7th annual congress (Florence); 2002.
27. Ljungman P., Aschan J., Lewensohn-Fuchs I., et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 66 (1998) 1330-1334
28. Kanda Y., Mineishi S., Saito T., et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 28 (2001) 689-692
29. Meyers J.D., Reed E.C., Shepp D.H., et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 318 (1988) 70-75
30. Al-Sagheir AI, Foley RS, Leber B, Wasi P, Walker IR. Ganciclovir prophylaxis is associated with delayed neutrophil engraftment in patients undergoing haploidentical transplantation. In: American Society of Hematology 45th annual meeting (San Diego, California); 2003. p. 5483.
31. Nozzoli C, Bartolozzi B, Guidi S, et al. Aciclovir versus ganciclovir plus foscarnet for CMV prophylaxis in allogeneic haematopoietic stem cell transplantation. In: 3rd Annual meeting of the European Group for blood and marrow transplantation 23rd meeting of the EBMT nurses group 6th meeting of the EBMT data management group (Lyon, France); 2007.
32. Baronciani D, Angelucci E, Lucarelli G, et al. Anti-cmv prophylaxis after transplant significally reduces the risk of disease in thalassemic patients. In: 28th Annual meeting of the European Group for blood and marrow transplantation, 18th meeting of the EBMT nurses group and 1st meeting of the EBMT data management group; 2002.
33. Irving I, Williamson J, Mollee P, et al. Low dose valaciclovir for the prevention of CMV disease post allogeneic bone marrow transplantation. In: 27th Annual meeting European Group for blood and marrow transplantation and 17th nurses group meeting (Maastricht, The Netherlands); 2001.
34. Quilitz R, Avila J, Greene J, Goldstein S, Fields K. Low dose oral famciclovir is adequate herpes simplex virus prophylaxis in patients undergoing high dose therapy and autologous stem cell rescue. In: ASCO annual meeting; 1999.
35. Ambinder R.F., Burns W.H., Lietman P.S., and Saral R. Prophylaxis: a strategy to minimise antiviral resistance. Lancet 1 (1984) 1154-1155
36. Redding S.W., and Montgomery M.T. Acyclovir prophylaxis for oral herpes simplex virus infection in patients with bone marrow transplants. Oral Surg Oral Med Oral Pathol 67 (1989) 680-683
37. Cantero S, Sanz G, Jarque I, et al. Cytomegalovirus (CMV) infection and disease after unrelated cord blood transplantation (UCBT) in CMV-positive adults receiving ganciclovir (GCV) OR valganciclovir (VGC) prophylaxis. In: 46th Interscience conference on antimicrobial agents and chemotherapy (San Francisco, California); 2006. p. V-2019.
38. Qureshi A, Seiter K, Ahmed T, Nelson J, Liu D. Valgancyclovir significantly reduced reactivation of CMV following mini-transplantation with map (mitoxantrone, Ara-C, and pentostatin) regimen. In: American Society of Hematology 46th annual meeting (San Diego, California); 2004. p. 5082.
39. Pinazzi MB, Carnevalli EC, Severino A, et al. Foscarnet or acyclovir as prophylaxis for cytomegalovirus reactivation and disease in allogeneic haematopoietic stem cell transplantation from alternative donors. In: 23rd Meeting of the EBMT nurses group 6th meeting of the EBMT data management group (Lyon, France); 2007.
40. Orlowski R.Z., Mills S.R., Hartley E.E., et al. Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Leuk Lymphoma 45 (2004) 2215-2219
41. Szer J., Durrant S., Schwarer A.P., et al. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. Intern Med J 34 (2004) 98-101
42. Suh C, Ko OB, Kim S, Cho YH. Antimicrobial prophylaxis against infectious complications of autologous stem cell transplantation: a randomized phase III study. In: European Hematology Association - 11th annual congress (Amsterdam); 2006.
43. Suh C., Ko O.B., Kim S., and Cho Y.H. Antimicrobial prophylaxis against infectious complications of autologous stem cell transplantation: a randomized phase III study. Korean J Hematol 41 (2006) 282-288
44. Humar A., Hebert D., Davies H.D., et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 81 (2006) 856-861
45. Dunn D.L., Gillingham K.J., Kramer M.A., et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 57 (1994) 876-884
46. Kraemer K.G., Neiman P.E., Reeves W.C., and Thomas E.D. Prophylactic adenine arabinoside following marrow transplantation. Transpl Proc 10 (1978) 237-240
47. Meyers J.D., Flournoy N., Sanders J.E., et al. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med 107 (1987) 809-816
48. O'Brien S., Ravandi F., Riehl T., et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111 (2008) 1816-1819
49. O'Brien S, Ravandi F, Riehl T, et al. A randomized trial of valacyclovir versus valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab. In: Abstracts for the 47th annual meeting of the American Society of Hematology (Atlanta, Georgia); 2005. p. 2960.
50. Winston D.J., Baden L.R., Gabriel D.A., et al. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transpl 12 (2006) 635-640
51. Winston D.J., Baden L.R., Gabriel D.A., et al. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Blood (2004) 104 [abstr. 2223]
52. Park KW, Lee J, Park J, et al. A randomized trial of short-course preemptive ganciclovir compared with conventional ganciclovir therapy to prevent cytomegalovirus infection after allogeneic stem cell transplantation. In: 46th Annual meeting of the American Society of Hematology (San Diego, California); 2004. p. 3162.
53. Boeckh M., Englund J., Li Y., et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 44 (2007) 245-249
54. Einsele H., Reusser P., Bornhauser M., et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107 (2006) 3002-3008
55. Goodrich J.M., Mori M., Gleaves C.A., et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325 (1991) 1601-1607
56. Schmidt G.M., Horak D.A., Niland J.C., et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 324 (1991) 1005-1011
57. Moretti S., Zikos P., Van Lint M.T., et al. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transpl 22 (1998) 175-180
58. Mattes F.M., Hainsworth E.G., Geretti A.M., et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 189 (2004) 1355-1361
59. Ruiz I, Len O, Gurgui M, et al. Efficacy of valganciclovir as preemptive therapy or treatment for cytomegalovirus disease in haematopoietic stem cell transplantation: a prospective study from RESITRA/REIPI. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, Illinois); 2007. p. V-1201.
60. Ljungman P, Dahl H, Xu Y, Larsson K, Linde A. Effectiveness of Antiviral Agents against HHV-6 Excreted in Saliva in Stem Cell Transplant Recipients In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC); 2004. p. V-439.
61. Einsele H, Reusser P. On behalf of the IDWP of the EBMT. Prospective phase III randomised study of oral valgancyclovir vs. intravenous ganciclovir for pre-emptive therapy of CMV infection after allogeneic HSCT. In: 32nd Annual meeting of the European group for blood an marrow transplantation; 22nd meeting of the EBMT nurses group; 5th meeting of the EBMT data management group (Hamburg, Germany); 2006.
62. Shapira M. Valganciclovir in prevention of CMV reactivation following allo-SCT. NCT00330018.
63. Litzow M. The study is being done to see if taking the drug valganciclovir can prevent CMV infection. NCT00275665.
64. Nichols G. Valacyclovir in preventing CMV infection in patients who are undergoing donor stem cell transplantation. NCT 00045292.
65. Gluckman E., Lotsberg J., Devergie A., et al. Oral acyclovir prophylactic treatment of herpes simplex infection after bone marrow transplantation. J Antimicrob Chemother 12 Suppl. B (1983) 161-167
66. Gluckman E., Lotsberg J., Devergie A., et al. Use of acyclovir in the prevention of herpes infections after allogenic bone marrow grafts. Rev Fr Transfus Immunohematol 27 (1984) 391-396
67. Lundgren G., Wilczek H., Lonnqvist B., et al. Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis Suppl 47 (1985) 137-144
68. Ljungman P., Lonnqvist B., Gahrton G., et al. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 153 (1986) 840-847
69. Lundgren G., Wilczek H., Lönnqvist B., et al. Combined intravenous and oral prophylaxis with acyclovir in bone marrow transplant recipients. Transplant Proc 18 (1986) 126-129
70. Selby P., Powles R., Stolle K., and Stern H. Acyclovir for cytomegalovirus infection. Br Med J (Clin Res Ed) 289 (1984) 253
71. Selby P.J., Powles R.L., Easton D., et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 59 (1989) 434-438
72. Prentice H.G. Use of acyclovir for prophylaxis of herpes infections in severely immunocompromised patients. J Antimicrob Chemother 12 Suppl. B (1983) 153-159
73. Prentice H.G., and Hann I.M. Prophylactic studies against herpes infections in severely immunocompromised patients with acyclovir. J Infect 6 (1983) 17-21
74. Prentice H.G., and Hann I.M. Studies in the prophylaxis of herpes infections in severely immunocompromised patients using acyclovir. Schweiz Med Wochenschr Suppl 14 (1983) 26-29
75. Hann I.M., Prentice H.G., and Blacklock H.A. Acyclovir prophylaxis of herpes virus infections in severely immunocompromised patients: a randomized double blind controlled trial. Exp Hematol 10 (1982) 2-4
76. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir prophylaxis of herpes simplex virus infections after marrow transplant. In: 22nd Interscience conference on antimicrobial agents and chemotherapy (Washington, DC). American Society of Microbiology; 1982. p. 184.
77. Warkentin DI, Epstein JB, Campbell LM, et al. Valacyclovir (VAL) vs. acyclovir (ACV) in the prevention of mucocutaneous herpes simplex virus (HSV) infections in patients receiving a stem cell transplantation (SCT) or chemotherapy for hematologic malignancies. In: Infectious diseases society of America 38th annual meeting (New Orleans); 2000.
78. Warkentin D.I., Epstein J.B., Campbell L.M., et al. Valacyclovir (VAL) vs. acyclovir (ACV) in the prevention of mucocutaneous herpes simplex virus (HSV) infections in patients receiving a stem cell transplantation (SCT) or chemotherapy for hematologic malignancies. Blood (2000) 96 [abstr. 806]
79. Boeckh M., Gooley T.A., and Bowden R.A. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia. J Infect Dis 178 (1998) 1153-1157
80. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., and Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83 (1994) 1971-1979
81. Prentice H.G., Gluckman E., Powles R.L., et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Bone Marrow Transpl 19 (1997) 129-133
82. Ljungman P. Efficacy and safety of valaciclovir as prophylaxis against CMV infection and disease in BMT recipients. J Clin Virol 12 (1999) 167
83. Bergmann O.J., Mogensen S.C., Ellermann-Eriksen S., and Ellegaard J. Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 15 (1997) 2269-2274
84. Engelhard D., Morag A., Or R., et al. Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts. Isr J Med Sci 24 (1988) 145-150
85. Ljungman P., Wilczek H., Gahrton G., et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transpl 1 (1986) 185-192
86. Perren T.J., Powles R.L., Easton D., Stolle K., and Selby P.J. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med 85 (1988) 99-101
87. Winston D.J., Ho W.G., Bartoni K., et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 118 (1993) 179-184
88. Gluckman E., Lotsberg J., Devergie A., et al. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet 2 (1983) 706-708
89. Hann I.M., Prentice H.G., Blacklock H.A., et al. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. Br Med J (Clin Res Ed) 287 (1983) 384-388
90. Saral R., Burns W.H., Laskin O.L., Santos G.W., and Lietman P.S. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 305 (1981) 63-67
91. Shepp D.H., Dandliker P.S., Flournoy N., and Meyers J.D. Once-daily intravenous acyclovir for prophylaxis of herpes simplex virus reactivation after marrow transplantation. J Antimicrob Chemother 16 (1985) 389-395
92. Wade J.C., Newton B., Flournoy N., and Meyers J.D. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 100 (1984) 823-828
93. Liesveld J.L., Abboud C.N., Ifthikharuddin J.J., et al. Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. Biol Blood Marrow Transpl 8 (2002) 662-665
94. Warkentin D.I., Epstein J.B., Campbell L.M., et al. Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients. Ann Pharmacother 36 (2002) 1525-1531
95. Boeckh M., Gooley T.A., Myerson D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88 (1996) 4063-4071
96. Boeckh M., Kim H.W., Flowers M.E., Meyers J.D., and Bowden R.A. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation - a randomized double-blind placebo-controlled study. Blood 107 (2006) 1800-1805
97. Boeckh M., Nichols G., Chemaly R., et al. Prevention of late CMV disease after HCT: a randomized double-blind multicenter trial of valganciclovir (VGCV) prophylaxis versus PCR-guided GCV/VGCV preemptive therapy. Biol Blood Marrow Transpl 14 (2008) 30
98. Goodrich J.M., Bowden R.A., Fisher L., et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118 (1993) 173-178
99. Pineiro L., Skettino S., Tan J., and Stempien M.J. Efficacy of oral ganciclovir (GAN) for prevention of CMV infection following allogeneic bone marrow transplantation (BMT). Blood 90 (1997) 544a [abstr. 2425]
100. Prentice H.G., Gluckman E., Powles R.L., et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 343 (1994) 749-753
101. Shepp D.H., Dandliker P.S., Flournoy N., and Meyers J.D. Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients. Transplantation 43 (1987) 654-658
102. Winston D.J., Young J.A., Pullarkat V., et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 111 (2008) 5403-5410
103. Burns L.J., Miller W., Kandaswamy C., et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transpl 30 (2002) 945-951
104. Ljungman P., de La Camara R., Milpied N., et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 99 (2002) 3050-3056
105. Winston D.J., Yeager A.M., Chandrasekar P.H., et al. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 36 (2003) 749-758
106. Anderson H., Scarffe J.H., Sutton R.N., et al. Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. Br J Cancer 50 (1984) 45-49
107. Bergmann O.J., Ellermann-Eriksen S., Mogensen S.C., and Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ 310 (1995) 1169-1172
108. Lonnqvist B., Palmblad J., Ljungman P., et al. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer 1 (1993) 139-144
109. Saral R., Ambinder R.F., Burns W.H., et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 99 (1983) 773-776
110. Nichols W.G., Corey L., Gooley T., Davis C., and Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 185 (2002) 273-282
111. Ziemann M., Sedemund-Adib B., Reiland P., Schmucker P., and Hennig H. Increased mortality in long-term intensive care patients with active cytomegalovirus infection. Crit Care Med 36 (2008) 3145-3150
112. Murphy B.A. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 5 (2007) 13-21
113. Bellm L.A., Epstein J.B., Rose-Ped A., Martin P., and Fuchs H.J. Patient reports of complications of bone marrow transplantation. Support Care Cancer 8 (2000) 33-39
114. Morfin F., Bilger K., Boucher A., et al. HSV excretion after bone marrow transplantation: a 4-year survey. J Clin Virol 30 (2004) 341-345
115. Woo S.B., Sonis S.T., Monopoli M.M., and Sonis A.L. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 72 (1993) 1612-1617
116. Redding S.W. Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monogr (1990) 103-105
117. Junghanss C., Boeckh M., Carter R.A., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99 (2002) 1978-1985
118. Kalpoe J.S., van der Heiden P.L., Vaessen N., et al. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning. Bone Marrow Transpl 40 (2007) 137-143
119. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99 (2002) 4357-4363
120. Nachbaur D., Larcher C., Kircher B., et al. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation. Ann Hematol 82 (2003) 621-627
121. Schetelig J., Oswald O., Steuer N., et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transpl 32 (2003) 695-701
122. Wood L., Egger M., Gluud L.L., et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336 (2008) 601-605
123. Quinn B., Stone R., Uhlenhopp M., McCann S., and Blijlevens N. Ensuring accurate oral mucositis assessment in the European Group for Blood and Marrow Transplantation Prospective Oral Mucositis Audit. Eur J Oncol Nurs 11 Suppl. 1 (2007) S10-S18